CNTNAP2 and glioma: A small randomized trial has shown superiority of intravenous immunoglobulins (IVIG) to placebo in reducing seizure frequency in anti-leucine-rich, glioma-inactivated 1-antibody (anti-LGI1-Ab) and anti-contactin-associated protein-like 2-antibody (anti-CASPR2-Ab) seropositive adult patients (7).